Sphingosine kinase 2 (SK2), an enzyme that catalyzes the formation of bioactive lipid sphingosine 1-phosphate (S1P), has recently been identified as a viable target for therapeutic intervention in MM [28,29]. The gene discussed is SPHK2; the disease is Miyoshi myopathy.